Vermillion's Shares Spike to Lead Nasdaq | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of molecular diagnostics firm Vermillion rose 23 percent on Monday to close at $8.95, leading all gainers on the Nasdaq for the day.

The reason for the spike is unclear, as the firm didn't disclose any news or file any documents with the US Securities and Exchange Commission. Trading in the firm's shares also was heavy, with 603,100 shares trading hands, compared to its average daily volume of around 128,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.